During earnings season for the cannabis sector, some US-based companies are taking aim at Canadian marijuana firms, claiming that poor results from their neighbors to the north have driven down the entire industry.
The US cannabis market continues to trend towards rapid growth, with two multi-state operators (MSOs) putting up impressive numbers with the release of their quarterly results this week.
Growing revenue generation from US-based MSOs is something some analysts have suggested could close the valuation gap between companies in the US and their Canadian counterparts in the face of recent middling results from Canada’s cannabis giants.
Trulieve maintains grip on Florida cannabis market
Florida-based Trulieve started the trading day on Monday (November 18) on a positive note, up 2.6 percent to C$15.34 per share as of 11:30 a.m. EST.
The firm reported quarterly revenue of US$70.7 million, representing 22 percent quarter-over-quarter growth from the US$57.9 million it generated in Q2 2019.
The results exceeded analysts’ expectations, according to BNN Bloomberg.
The company also saw 19 percent growth in its patient numbers, attributed largely to the legalization of smokable flower, while also expanding its footprint across its home state with the addition of six more dispensaries in Florida.
During a call with investors and analysts, CEO Kim Rivers said while the firm is interested in increasing its market share across the US, it “will not grow for growth’s sake.” This decision has pushed Trulieve to launch an organic growth team tasked with applying strategically for cultivation and production licenses in undisclosed states.
Rivers went on to say the discouraging results from larger Canada-based cannabis producers are to blame for the pressure felt across the wider cannabis space since the summer of 2019.
“Their financial losses, writedowns and negative revenue trends are causing investors, both institutional and retail, to increasingly demand better results and holder value,” she said.
Trulieve still holds the top spot in Florida, one of the key states in the US according to analysts, when it comes to sales.
The company sold over 36 million milligrams of medical cannabis from November 8 to 14, as per the most recent information from the state’s Office of Medical Marijuana Use. The next largest seller, Surterra Wellness, is a distant second place having sold 9.3 million milligrams.
Ayr reports revenue growth in the face of vape ban
Ayr reported total revenue of US$32.1 million in Q3, a 19 percent increase from the US$26.9 million generated in Q2 2019.
The firm also announced it tightened losses from operations to US$10.7 million, down from US$20.1 million in the previous reporting period.
Jonathan Sandelman, CEO of Ayr, credited the company’s market share in Massachusetts for the quarterly growth seen. Monthly revenues for Ayr’s wholesale cannabis business in the eastern state have nearly tripled since the company’s qualifying transaction in May, the executive said.
Ayr CFO Brad Asher said the company generated US$4.2 million in cash flow from operations in Q3 to reinvest into funding cultivation expansion in Massachusetts and Nevada. That will more than double cultivation square footage for facilities in the two states.
Like Rivers, Sandelman went on to say the health of his firm contrasts with the struggle of the downtrodden cannabis sector.
“The capital markets are effectively closed for cannabis companies. Companies cannot raise any meaningful amount of cash and what they can raise is small amounts at very high capital costs,” he said, adding that Ayr’s cash flow gives it an upper hand.
Sandelman also said, however, that the company is preparing for volatility with added complexities in the fragmented regulatory environment in the US.
The cannabis space in one of Ayr’s key markets, Massachusetts, took a hit when the state’s governor put a four month ban on vape products in response to a growing vape-related health crisis.
Chief Operating Officer Jennifer Drake said the firm faced order cancelations in the aftermath of the ban, but the company is still aiming to reach its revised 2019 revenue projection of US$120 million to US$130 million, which was released on the same day the ban was announced.
Shares of Ayr dropped 2.2 percent from the market open on Tuesday (November 19) and sat at C$11.35 as of 10:32 a.m. EST.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.
Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ retail stores, today announced that its executive team will participate in the following conference in March 2021:
Needham 2 nd Annual Virtual Cannabis Conference, March 3, 2021: Management will participate in one-on-one meetings.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.